In August of 2008, company representatives from Abbott, Amgen, Eli Lilly & Company, Genentech, GlaxoSmithKline, MedImmune, an Pfizer were brought together to help advance the principles contained in ICH Q8(R2), Q9 and Q10, focusing on the principles of Quality by Design. The application of QbD to biotechnology products represents an important opportunity as the manufacturing and development of such products involves unique challenges with regard to both drug substance and drug product manufacturing due to the complexity of both the products and the biological manufacturing processes.Through a series of inter-company and regulatory interactions, the group set out to create a case study (“A-Mab: a Case Study in Bioprocess Development” – Version 2.1, October 30, 2009) that would stimulate discussion around how the core principles contained in these guidelines would be applied to product realization programs, with a multitude of ral world scenarios, as opposed to a singular approach.